Neuro-oncology advances最新文献

{"title":"Treatment-related survival patterns in diffuse intrinsic pontine glioma using a historical cohort: A report from the European Society for Pediatric Oncology DIPG/DMG Registry.","authors":"Joshua N Baugh, Sophie Veldhuijzen van Zanten, Marta Fiocco, Niclas Colditz, Marion Hoffmann, Geert O Janssens, Chiara Valentini, Darren Hargrave, Maria Wiese, André O von Bueren, Michael Karremann, Thomas Perwein, Gunther Nussbaumer, Martin Benesch, Dominik Sturm, Gerrit H Gielen, Mechthild Krause, Matthias Eyrich, Eelco W Hoving, Brigitte Bison, Dannis G van Vuurden, Christof M Kramm","doi":"10.1093/noajnl/vdae155","DOIUrl":"10.1093/noajnl/vdae155","url":null,"abstract":"<p><strong>Background: </strong>Our aim is to investigate the association of treatment with survival in patients with diffuse intrinsic pontine glioma (DIPG) by examining 6 historical treatment paths.</p><p><strong>Methods: </strong>We retrospectively analyzed data from 409 patients with radiologically centrally reviewed DIPG, sourced from the German Society of Pediatric Oncology and Hematology HIT-HGG trial database and the SIOPE-DIPG/DMG Registry. Survival outcomes were estimated using the Kaplan-Meier method, and univariable and multivariable Cox proportional hazard models were estimated to study treatment effects.</p><p><strong>Results: </strong>The median overall survival (OS) from diagnosis was 11.2 months (95% confidence interval [CI], 10.5-11.9). Patients who by choice received no frontline treatment had an OS of 3.0 months (95% CI, 2.0-4.0), while those treated with radiation therapy (RT) alone had a median OS of 10.4 months (95% CI, 9.1-11.8). Those receiving RT combined with chemotherapy had the longest median OS of 11.7 months (95% CI, 10.8-12.6). The median post-progression survival (PPS) was 4.1 months (95% CI, 3.5-4.7). Patients who relapsed and did not receive treatment had a PPS of 2.2 months (95% CI, 1.8-2.6), while those treated with chemotherapy alone had a PPS of 4.4 months (95% CI, 3.7-5.0), and those who underwent reirradiation, with or without chemotherapy, had the longest survival after relapse of 6.6 months (95% CI, 5.3-8.0). Treatment differences remained significant in multivariable analysis adjusted for age and symptom duration in both diagnosis and relapse setting.</p><p><strong>Conclusions: </strong>This study shows increased survival outcomes associated with radiation and chemotherapy treatment or a combination thereof, at diagnosis and relapse, in a historical DIPG cohort.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae155"},"PeriodicalIF":3.7,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11582646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142712351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of H3K27M alteration in midline gliomas of the brain using radiomics: A multi-institute study.","authors":"Abhilasha Indoria, Ankit Arora, Ajay Garg, Richa S Chauhan, Aparajita Chaturvedi, Manoj Kumar, Subhas Konar, Nishanth Sadashiva, Shilpa Rao, Jitender Saini","doi":"10.1093/noajnl/vdae153","DOIUrl":"10.1093/noajnl/vdae153","url":null,"abstract":"<p><strong>Background: </strong>Noninvasive prediction of H3K27M-altered Diffuse midline gliomas is important because of the involvement of deep locations and proximity to eloquent structures. We aim to predict H3K27M alteration in midline gliomas using radiomics features of T2W images.</p><p><strong>Methods: </strong>Radiomics features extracted from 124 subjects (69 H3K27M-altered/55 H3K27M-wild type). T2W images were resampled to 1 × 1 × 1mm³ voxel size, preprocessed, and normalized for artifact correction, intensity variations. The feature set was normalized and subjected to reduction by variance thresholding, correlation coefficient thresholding, and sequential feature selector. Adaptive synthesis oversampling technique was used to oversample the training data. Random forest classifier (RFC), Decision tree classifier (DTC), and K-nearest neighbors classifier (KNN) were trained over the training dataset and the performance was assessed over the internal test dataset and external test data set (52 subjects: 33 H3K27M-altered/19-H3K27M-wild type).</p><p><strong>Results: </strong>DTC achieved a validation score of 77.33% (5-fold cross-validation) and an accuracy of 80.64%, 75% on internal and external test datasets. RFC achieved a validation score of 80.7% (5-fold cross-validation) an accuracy of 80.6%, and 73% on internal and external test datasets. DTC achieved a validation score of 78.67% (5-fold cross-validation) an accuracy of 80.64%, and 61.53% on internal and external test datasets. The accuracy score of DTC, RFC, and KNN on the internal test dataset was approximately 80% while on the external test dataset, DTC achieved 75% accuracy, RFC achieved 73% accuracy and KNN achieved 65.1% accuracy.</p><p><strong>Conclusions: </strong>H3K27M alteration is a potential immunotherapeutic marker and is associated with poor prognosis and radiomics features extracted from conventional T2W-images can help in identifying H3K27M-altered cases non-invasively with high precision.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae153"},"PeriodicalIF":3.7,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11600333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142741794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spinal neuro-oncology-Not an appendix of neuro-oncology.","authors":"Suganth Suppiah, Ivo Tremont-Lukats, Manfred Westphal","doi":"10.1093/noajnl/vdae146","DOIUrl":"10.1093/noajnl/vdae146","url":null,"abstract":"","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 Suppl 3","pages":"iii1-iii2"},"PeriodicalIF":3.7,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical, molecular, and genetic features of spinal meningiomas.","authors":"Dylan Deska-Gauthier, Laureen D Hachem, Justin Z Wang, Alex P Landry, Leeor Yefet, Chloe Gui, Yosef Ellengbogen, Jetan Badhiwala, Gelareh Zadeh, Farshad Nassiri","doi":"10.1093/noajnl/vdae123","DOIUrl":"10.1093/noajnl/vdae123","url":null,"abstract":"<p><p>Spinal meningiomas comprise 25%-46% of all primary spinal tumors. While the majority are benign and slow-growing, when left untreated, they can result in significant neurological decline. Emerging clinical, imaging, and molecular data have begun to reveal spinal meningiomas as distinct tumor subtypes compared to their intracranial counterparts. Moreover, recent studies indicate molecular and genetic subtype heterogeneity of spinal meningiomas both within and across the classically defined WHO grades. In the current review, we focus on recent advances highlighting the epidemiological, pathological, molecular/genetic, and clinical characteristics of spinal meningiomas. Furthermore, we explore patient and tumor-specific factors that predict prognosis and postoperative outcomes. We highlight areas that require further investigation, specifically efforts aimed at linking unique molecular, genetic, and imaging characteristics to distinct clinical presentations to better predict and manage patient outcomes.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 Suppl 3","pages":"iii73-iii82"},"PeriodicalIF":3.7,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor volume features predict survival outcomes for patients diagnosed with diffuse intrinsic pontine glioma.","authors":"D'Andre Spencer, Erin R Bonner, Carlos Tor-Díez, Xinyang Liu, Kristen Bougher, Rachna Prasad, Heather Gordish-Dressman, Augustine Eze, Roger J Packer, Javad Nazarian, Marius George Linguraru, Miriam Bornhorst","doi":"10.1093/noajnl/vdae151","DOIUrl":"10.1093/noajnl/vdae151","url":null,"abstract":"<p><strong>Background: </strong>Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood central nervous system tumor. Diagnosis and monitoring of tumor response to therapy is based on magnetic resonance imaging (MRI). MRI-based analyses of tumor volume and appearance may aid in the prediction of patient overall survival (OS).</p><p><strong>Methods: </strong>Contrast-enhanced T1- and FLAIR/T2-weighted MR images were retrospectively collected from children with classical DIPG diagnosed by imaging (<i>n</i> = 43 patients). MRI features were evaluated at diagnosis (<i>n</i> = 43 patients) and post-radiation (<i>n</i> = 40 patients) to determine OS outcome predictors. Features included 3D tumor volume (T_wv), contrast-enhancing tumor core volume (T_c), T_c relative to T_wv (T_C/T_wv), and T_wv relative to whole brain volume. Support vector machine (SVM) learning was used to identify feature combinations that predicted OS outcome (defined as OS shorter or longer than 12 months from diagnosis).</p><p><strong>Results: </strong>Features associated with poor OS outcome included the presence of contrast-enhancing tumor at diagnosis, >15% T_c/T_wv post-radiation therapy (RT), and >20% ∆Tc/T_wv post-RT. Consistently, SVM learning identified T_c/T_wv at diagnosis (prediction accuracy of 74%) and ∆T_c/T_wv at <2 months post-RT (accuracy = 75%) as primary features of poor survival.</p><p><strong>Conclusions: </strong>This study demonstrates that tumor imaging features at diagnosis and within 4 months of RT can predict differential OS outcomes in DIPG. These findings provide a framework for incorporating tumor volume-based predictive analyses into the clinical setting, with the potential for treatment customization based on tumor risk characteristics and future applications of machine-learning-based analysis.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae151"},"PeriodicalIF":3.7,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142484591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroanatomical profiles of cognitive phenotypes in patients with primary brain tumors.","authors":"Jiwandeep S Kohli, Anny Reyes, Austin Hopper, Alena Stasenko, Natalia Menendez, Kathryn R Tringale, Mia Salans, Roshan Karunamuni, Jona A Hattangadi-Gluth, Carrie R McDonald","doi":"10.1093/noajnl/vdae152","DOIUrl":"10.1093/noajnl/vdae152","url":null,"abstract":"<p><strong>Background: </strong>Patients with brain tumors demonstrate heterogeneous patterns of cognitive impairment, likely related to multifactorial etiologies and variable tumor-specific factors. Cognitive phenotyping offers a patient-centered approach to parsing heterogeneity by classifying individuals based on patterns of impairment. The aim of this study was to investigate the neuroanatomical patterns associated with each phenotype to gain a better understanding of the mechanisms underlying impairments.</p><p><strong>Methods: </strong>Patients with primary brain tumors were recruited for a prospective, observational study. Patients were cognitively phenotyped using latent profile analysis in a prior study, revealing 3 distinct groups: <i>generalized</i>, <i>isolated verbal memory</i>, and <i>minimal impairment</i>. Whole brain cortical thickness (CT), fractional anisotropy, and mean diffusivity (MD) were compared across phenotypes, and associations between imaging metrics and cognitive scores were explored.</p><p><strong>Results: </strong>Neurocognitive, structural MRI, and diffusion MRI data were available for 82 participants at baseline. Compared to the minimal impairment group, the generalized impairment group showed a widespread, bi-hemispheric pattern of decreased CT (<i>P</i>-value range: .004-.049), while the verbal memory impairment group showed decreased CT (<i>P</i>-value range: .006-.049) and increased MD (<i>P</i>-value range: .015-.045) bilaterally in the temporal lobes. In the verbal memory impairment group only, increased parahippocampal MD was associated with lower verbal memory scores (<i>P</i>-values < .01).</p><p><strong>Conclusions: </strong>Cognitive phenotypes in patients with brain tumors showed unique patterns of brain pathology, suggesting different underlying mechanisms of their impairment profiles. These distinct patterns highlight the biological relevance of our phenotyping approach and help to identify areas of structural and microstructural vulnerability that could inform treatment decisions.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae152"},"PeriodicalIF":3.7,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142368098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.","authors":"Matthias Holdhoff, Xiaobu Ye, Roy E Strowd, Burt Nabors, Tobias Walbert, Frank S Lieberman, Stephen J Bagley, John B Fiveash, Joy D Fisher, Serena Desideri, Trisha Surakus, Marc Engelhardt, Thomas Kaindl, Heidi A Lane, Karine Litherland, Stuart A Grossman, Lawrence R Kleinberg","doi":"10.1093/noajnl/vdae150","DOIUrl":"10.1093/noajnl/vdae150","url":null,"abstract":"<p><strong>Background: </strong>Lisavanbulin (BAL101553) is a small, lipophilic, oral microtubule destabilizer with promising antitumoral activity observed in preclinical glioblastoma (GBM) models.</p><p><strong>Methods: </strong>This multicenter phase 1 study sought to determine the MTD of oral Lisavanbulin in combination with standard RT (60 Gy/30 fractions) but without temozolomide in patients with newly diagnosed MGMT promoter unmethylated GBM (uGBM). Dose escalation followed a modified 3 + 3 design. Secondary objectives included estimation of OS and PFS and pharmacokinetic analysis.</p><p><strong>Results: </strong>Twenty-six patients with uGBM (median age, 63 years, 42.3% male, 61.5% with gross total resection, median Karnofsky performance status 80) were enrolled; 2 tumors had an IDH1 mutation. Predefined dose levels of Lisavanbulin, administered daily concomitantly with RT, were: 4 mg (5 pts), 6 mg (5 pts), 8 mg (7 pts), 12 mg (5 pts), and 15 mg (4 pts). The initial starting dose was 8 mg. Due to grade 4 aseptic meningoencephalitis in the first patient, the dose was decreased to 4 mg. Dose escalation resumed and continued to 15 mg with dose-limiting toxicities of grade 2 confusion and memory impairment observed at 12 mg. Avanbulin exposures increased in a relatively dose-proportional manner with increasing oral dose of Lisavanbulin from 4 to 15 mg.</p><p><strong>Conclusions: </strong>Lisavanbulin in combination with RT was considered safe up to the highest predefined oral dose level of 15 mg daily.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae150"},"PeriodicalIF":3.7,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450402/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142383057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aggressive high-grade NF2 mutant meningiomas downregulate oncogenic YAP signaling via the upregulation of VGLL4 and FAT3/4.","authors":"Abigail G Parrish, Sonali Arora, H Nayanga Thirimanne, Dmytro Rudoy, Sebastian Schmid, Philipp Sievers, Felix Sahm, Eric C Holland, Frank Szulzewsky","doi":"10.1093/noajnl/vdae148","DOIUrl":"10.1093/noajnl/vdae148","url":null,"abstract":"<p><strong>Background: </strong>Meningiomas are the most common primary central nervous system tumors in adults. Although generally benign, a subset is of higher grade and ultimately fatal. Around half of all meningiomas harbor inactivating mutations in NF2, leading to deregulation of oncogenic YAP1 activity. While benign NF2 mutant meningiomas exhibit few genetic events in addition to NF2 inactivation, aggressive high-grade NF2 mutant meningiomas frequently harbor a highly aberrant genome. It is unclear if NF2 mutant meningiomas of different grades are equally reliant on YAP activity.</p><p><strong>Methods: </strong>We analyzed bulk and single-cell RNA-Seq data from a large cohort of human meningiomas for the expression of YAP1 target genes and Hippo effectors as well as in vitro cell line experiments.</p><p><strong>Results: </strong>Aggressive NF2 mutant meningiomas harbor decreased expression levels of YAP1 target genes and increased expression levels of the YAP1 antagonist VGLL4 and the upstream regulators FAT3/4 compared to their benign counterparts. Decreased expression of YAP1 target genes as well as high expression of VGLL4 and FAT3/4 is significantly associated with an increased risk of recurrence. In vitro, overexpression of VGLL4 resulted in the downregulation of YAP activity in benign NF2 mutant meningioma cells, confirming the direct link between VGLL4 expression and decreased levels of YAP activity observed in aggressive NF2 mutant meningiomas.</p><p><strong>Conclusions: </strong>Our results shed new insight into the biology of benign and aggressive NF2 mutant meningiomas and may have important implications for the efficacy of therapies targeting oncogenic YAP1 activity in NF2 mutant meningiomas.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae148"},"PeriodicalIF":3.7,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459063/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Landscape and impact of mind-body, cognitive-behavioral, and physical activity interventions in adolescent and adult brain tumor patients: A systematic review.","authors":"Alex R Wollet, James L Rogers, Sefanit Berhanu, Ciara Locke, Madhura Managoli, Emily Wu, I Diane Cooper, Terri S Armstrong, Amanda L King","doi":"10.1093/noajnl/vdae134","DOIUrl":"10.1093/noajnl/vdae134","url":null,"abstract":"<p><strong>Background: </strong>The use of mind-body, cognitive-behavioral, and physical activity interventions have shown efficacy for improving symptom burden and functional limitations in other cancers; however, these strategies have not been widely implemented within neuro-oncology. This systematic review describes the current landscape and the impact of these interventions on adolescent and adult patients with brain tumors, which may guide the development of future interventions.</p><p><strong>Methods: </strong>A systematic search of PubMed, Embase, and Web of Science was performed using preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines with predefined eligibility criteria. Twenty-nine studies met the inclusion criteria and were selected for review.</p><p><strong>Results: </strong>There was promising evidence for the feasibility and efficacy of mind-body and physical activity interventions for improving mood and quality of life, as well as enhanced physical functioning following aerobic and strength-based interventions. Results were mixed for cognitive-behavioral interventions, likely due to underpowered analyses. Interventions tested in pediatric patients also showed improvements in fatigue, mood, and quality of life, though these individuals represented a small proportion of the pooled sample.</p><p><strong>Conclusions: </strong>Findings suggest that mind-body and physical activity interventions can improve both physical and psychological health for patients with brain tumors, though additional well-designed clinical trials are needed to better establish efficacy.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae134"},"PeriodicalIF":3.7,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142368097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oligodendroglioma patient survival is associated with circulating B-cells and age.","authors":"Jennie W Taylor, Gayathri Warrier, Helen M Hansen, Lucie McCoy, Terri Rice, Geno Guerra, Stephen S Francis, Jennifer L Clarke, Paige M Bracci, Sara Hadad, Karl T Kelsey, Margaret Wrensch, Annette M Molinaro, John K Wiencke","doi":"10.1093/noajnl/vdae143","DOIUrl":"10.1093/noajnl/vdae143","url":null,"abstract":"<p><strong>Background: </strong>Variations in survival among patients with oligodendroglioma are unexplained by known prognostic factors. To assess the impact of peripheral immune profiles on prognosis, we applied immunomethylomics analyses-DNA methylation of archived whole blood samples, to characterize immune cells.</p><p><strong>Methods: </strong>We compared the proportions of immune cells from patients with oligodendroglioma to other glioma subtypes and controls. We used recursive partitioning analysis (RPA) within the oligodendrogliomas to correlate with survival.</p><p><strong>Results: </strong>Patients with oligodendrogliomas (141) were median age at diagnosis of 44 years; 57% male; 75% White; 60% prior chemotherapy; and 25% on dexamethasone at sample collection. Patients with oligodendrogliomas had immune profiles more similar to controls than other glioma subtypes, though with notably lower B-cells. RPA of patients with oligodendrogliomas delineated 2 survival groups based on an interaction between age and B-naïve cells. Patients with longer survival (median 24.2 years) were ≤42 years of age with higher B-naïve cells versus worse survival (median 16.9 years) who were ≤42 years of age with lower B-naïve cells or >42 years of age (<i>P</i> = .00032). Patients with worse survival also had lower CD4- and CD8-naïve T-cells. Similar immune profiles were observed in an independent cohort of oligodendroglioma patients prior to surgery.</p><p><strong>Conclusions: </strong>Peripheral blood immune profiles in oligodendroglioma suggested that younger patients with lower B-naïve cells experienced shorter survival. Though our findings lack of validation cohort and use a heterogenous patient population, they suggest peripheral blood immune profiles may be prognostic for patients with glioma and warrant further investigation.</p>","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"6 1","pages":"vdae143"},"PeriodicalIF":3.7,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11379917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142157073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}